U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799468) titled 'Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation' on Jan. 23.
Brief Summary: Liver transplantation (LT) is the best treatment option for patients with early stages of hepatocellular carcinoma (HCC).1 However, the use of LT depends on maintaining a balance between the risk of post-transplant recurrence or HCC-related death and the equitable distribution of organ donors.2-5 Current selection criteria aim to avoid transplant futility by excluding patients from LT who are at a high risk of tumor recurrence. Selecting patients within the Milan criteria has been shown to provide excellent patient outco...